Logo Geneseeq
  • Services
    • Genomic Testing
      • Companion Diagnostic Test
      • Laboratory Developed Tests (LDT)
        • Solid Tumors
        • Hematologic Malignancies
        • Hereditary Cancers
        • Minimal Residual Disease
      • RUO Kit Solution
    • Research Services
      • Platforms
      • DNA Sequencing
      • RNA Sequencing
      • Other Services
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
  • Join Us
  • Contact Us
  • Ch|中文
  • Search

August 22, 2023

Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer


by Geneseeq

May 25, 2023

GENESEEQ TO SHOWCASE NEW FINDINGS AT ASCO 2023


by Geneseeq

May 16, 2023

Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer


by Geneseeq

March 16, 2021

Geneseeq Collaborates with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS kit


by Geneseeq

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info.toronto@geneseeq.com

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2023 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences